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ABSTRACT
Mutations in the GnRH receptor (GNRHR) have been described as
a cause of reproductive failure in a subset of patients with idiopathic
hypogonadotropic hypogonadism (IHH). Given the apparent rarity of
these mutations, we set out to determine the frequency and distri-
bution of GNRHR mutations in a heterogeneous population of pa-
tients with IHH who were well characterized with respect to diag-
nosis, phenotype, and mode of inheritance and to define their
distribution within the receptor protein.
One hundred and eight probands with IHH were screened for
mutations in the coding sequence of GNRHR. Forty-eight of the 108
patients had a normal sense of smell, whereas the remaining 60 had
anosmia or hyposmia (Kallmann syndrome). Exon segments in the
GNRHR were screened for mutations using temperature gradient gel
electrophoresis, and all mutations were confirmed by direct
sequencing.
Five unrelated probands (3 men and 2 women), all normosmic,
were documented to have changes in the coding sequence of the
GNRHR. Two of these probands were from a subgroup of 5 kindreds
consistent with a recessive mode of inheritance, establishing a
GNRHR mutation frequency of 2 of 5 (40%) in patients with normos-
mic, autosomal recessive IHH. The remaining 3 probands with
GNRHR mutations were from a subgroup of 18 patients without
evidence of familial involvement, indicating a prevalence of 3 of 18
(16.7%) in patients with sporadic IHH and a normal sense of smell.
Among the five individuals bearing GNRHR mutations, a broad
spectrum of phenotypes was noted, including testicular sizes in the
male that varied from prepubertal to the normal adult male range.
Three probands had compound heterozygous mutations, and two had
homozygous mutations. Of the eight DNA sequence changes identi-
fied, four were novel: Thr32Ile, Cys200Tyr, Leu266Arg, and Cys279Tyr.
COS-7 cells transiently transfected with complementary DNAs en-
coding the human GNRHR containing each of these four novel mu-
tations failed to respond to GnRH agonist stimulation.
We conclude that 1) the spectrum of phenotypes in patients with
GNRHR mutations is much broader than originally anticipated; 2)
the frequency of GNRHR mutations may be more common than pre-
viously appreciated in familial cases of normosmic IHH and infre-
quent in sporadic cases; and 3) functional mutations of the GNRHR
are distributed widely throughout the protein. (J Clin Endocrinol
Metab 86: 1580–1588, 2001)
IN THE CLINICAL syndrome of idiopathic hypogonado-tropic hypogonadism (IHH), affected individuals present
with delayed sexual development and inappropriately low go-
nadotropin and sex steroid levels in the absence of anatomical
or functional abnormalities of the hypothalamic-pituitary axis.
There are many subtypes of IHH, including congenital IHH
with anosmia [Kallmann syndrome (KS)] and IHH with adre-
nal insufficiency (adrenal hypoplasia congenita). Isolation of
the gene responsible for X-linked KS (KAL) has led to a patho-
physiological model correlating GnRH deficiency with abnor-
mal olfactory bulb development (1–3). Mutations in the
X-linked gene for adrenal hypoplasia congenita, DAX1, have
also uncovered the crucial role of this orphan nuclear hormone
receptor at multiple levels of the reproductive axis (4–6). De-
spite these discoveries, until recently little has been known
about the genes that cause isolated IHH without anosmia or
adrenal insufficiency.
The GnRH receptor gene (GNRHR, 4q21.2), encodes a
seven-transmembrane domain G protein-coupled receptor,
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but lacks the intracellular carboxyl-terminus typically seen in
other members of this family (7, 8). Although an obvious
candidate gene for IHH, the nearly universal response of
such patients to exogenous pulsatile GnRH initially made the
candidacy of this gene seem unlikely (9). However, 3 yr ago,
compound heterozygous mutations in the GNRHR were
identified in a family with IHH (10). Now, numerous com-
pound heterozygotes (10–14) and one homozygous (15)
GNRHR mutation(s) have been described, causing subtypes
of IHH varying from complete to partial resistance to GnRH.
The purpose of this study was to determine the prevalence
of GNRHR mutations in a large population of well pheno-
typed patients with IHH (classified according to mode of
inheritance) and establish genotype/phenotype correlations
where possible. These studies demonstrate that GNRHR mu-
tations can cause a broad range of reproductive phenotypes.
GNRHR mutations, which appear to be distributed through-
out the receptor, account for a larger proportion of both
familial and sporadic cases of IHH than previously
appreciated.
Experimental Subjects
In vivo studies
The diagnosis of IHH was based on the absence of spontaneous
puberty by age 18 yr and hypogonadal sex steroid levels (testosterone,
#3.5 nmol/L; estradiol, #73 pmol/L) in the setting of inappropriately
normal or low gonadotropin levels. In 65 of our 108 patients (60%),
additional evidence for a diagnosis of IHH was provided by 1) the
absence of normal pulsatile gonadotropin secretion during 12–24 h of
frequent (every 10 min) blood sampling (16, 17); 2) normal basal and
stimulated levels of TSH, PRL, GH, and cortisol on baseline and stim-
ulation testing; and 3) no evidence of a mass lesion on imaging of the
hypothalamic-pituitary region.
One hundred and eight unrelated probands from well characterized
pedigrees were screened for mutations of the GNRHR. Patients were
divided into three diagnostic categories: 1) idiopathic, congenital
IHH/KS (n 5 87), 2) partial IHH/KS (n 5 14), and 3) acquired or
adult-onset IHH (n 5 7). Patients were categorized as having partial IHH
if low amplitude LH pulses were detectable during every 10 min blood
sampling using modified Santen and Bardin pulse analysis or if the
clinical history was consistent with partial pubertal development. Pa-
tients were categorized as having adult-onset IHH if they had under-
gone age-appropriate spontaneous sexual maturation by history (with
proven paternity in some cases), but subsequently developed isolated
IHH without an identifiable cause (18).
Fifty healthy volunteers (consecutive donors to the Massachusetts
General Hospital blood bank) were also screened for mutations of the
GNRHR.
Modes of inheritance
Genetic criteria were used to establish the likely mode of disease
transmission as outlined in previous analyses (19). A family was clas-
sified as X-linked if only males were affected and unaffected females
could be considered carriers. There could be no male to male transmis-
sion. A family was classified as autosomal recessive if all affected in-
dividuals were members of the same generation and included at least
one female. Consanguinity provided additional support for this desig-
nation. A family was classified as autosomal dominant if direct trans-
mission of the phenotype was demonstrable across generations, even if
incomplete expressivity was present. Male to male transmission was
considered definitive evidence for dominant inheritance. Delayed pu-
berty and isolated anosmia were used as surrogate markers of the
phenotype (19).
Clinical phenotyping: baseline frequent sampling
When possible, patients were admitted to the General Clinical Research
Center of the Massachusetts General Hospital for phenotyping studies.
Blood samples were collected every 10 min for 12–24 h for measurement
of LH in 65 of the 108 patients. Pulsatile hormone secretion was assessed
using the modified version of the Santen and Bardin method as previously
described (20, 21). Gonadotropin responses to a single bolus of 100 mg
GnRH were also assessed. This study was approved by the subcommittee
on human studies of the Massachusetts General Hospital; all subjects gave
informed consent before participating.
Materials and Methods
In vivo studies
The serum LH and FSH concentrations of patients 1, 2, 3, and 5 were
determined by one of two methods. 1) Immunoassays were calibrated
against the Second International Reference Preparation of human meno-
pausal gonadotropin (WHO 71/223) (22–24), with a minimal detectable
dose of 0.8 IU (WHO 71/223)/L. Inter- and intraassay coefficients of
variation were less than 10%. Free-a subunit was measured by a mono-
clonal antibody RIA, using a highly purified a-subunit of hCG as the
standard (25, 26). 2) A microparticle enzyme immunoassay was per-
formed using the automated Abbott AxSYM system, with the Second
International Reference Preparation as the reference standard. The assay
sensitivity for both LH and FSH was 1.6 mIU/mL. The intraassay co-
efficients of variation (CVs) for LH and FSH were less than 7% and 6%,
respectively, with interassay CVs for both hormones of less than 7.4%.
Serum testosterone concentrations were measured using the Coat-A-
Count RIA kit (Diagnostic Products, Los Angeles, CA), which had intra-
and interassay CVs of less than 10%. Estradiol (E2) was measured by the
AxSYM system (Abbott Laboratories, Chicago, IL), which had an ana-
lytical sensitivity of 36.7 pmol/L and a functional sensitivity of 73.4
pmol/L. The intraassay CV was less than 6.4% with an interassay CV
less than 10.6%.
In vitro studies
Mutational analysis. Genomic DNA was extracted from peripheral blood
leukocytes or cultured white blood cells. Melting map analysis was
performed for each exon fragment using Winmelt software (Bio-Rad
Laboratories, Inc., Hercules, CA). When necessary, exon fragments were
split, and primers for exon amplification were selected using Lasergene
software (DNASTAR, Inc., Madison, WI). A 40-mer GC clamp [(GC)n
CGCCCGCCGCGCCCCGCGCCCGCCCCGCCGCCCCCGCCCC] was
attached to the 59-end of either the forward or the reverse primer to
prevent strand melting. Three sets of primers were used to amplify exon
1: sense, 59-ACACAAGGCTTGAAGCTCTGTCCCT-39; antisense, 59-
(GC)n TCTTTCTTCTGTGTCCACTTCTGA-39; sense, 59-CCACTCT-
GACCTTGTCTGGAAAG-39; antisense, 59-(GC)n AGCTTTAGATA-
ACTGAGAACTTTGC-39; and sense, 59-AACATCTGACCTTAGC-
CAACCTG-39; antisense, 59-(GC)n CAAGGTAACAGAACAGAG-
CCAGAA-39. One primer pair was used to amplify exon 2: sense, 59-
(GC)n AGGAGCTTAGAAATTGCTTTAGGTA-39; antisense, 59-TGC-
TATTTAAAAACTGCCCACAA-39. Two primer pairs were used to am-
plify exon 3: sense, 59-(GC)n GCTGTCTTCCTTTTTGTCCACTTTG-39;
antisense, 59-CAATACCAAATCCTAGGACATAG-39; and sense, 59-
CACTTCATTTACTGTCTGCTGGAC-39; antisense, 59-(GC)n ATTCAT-
TACCTTACCCTTCTTCATA-39. Reactions were performed in a final
volume of 100 mL containing 50 pmol of each PCR primer, 200 mmol of
each deoxy-NTP, 2.5 U Taq polymerase, and 10 mmol/L Tris-HCl (pH
8.3). PCR reactions were carried out for 35 cycles: denaturing at 94 C for
30 s, annealing at 53–58 C for 30 s, and elongation at 72 C for 30 s. The
quality and predicted molecular size of each PCR product were assessed
by electrophoresis through a 1% agarose gel.
Temperature gradient gel electrophoresis (TGGE)
Given the large number of individuals screened for mutations, TGGE,
a mutation detection method that can separate two DNA fragments that
differ in sequence by as little as a single base substitution, was employed
(27, 28). The TGGE apparatus is a horizontal acrylamide slab gel (Diagen,
Dusseldorf, Germany) placed on a horizontal aluminum platform per-
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fused with water at a specified temperature gradient maintained by a
digitally controlled heater bath (NESLAB Instruments, Portsmouth,
NH). Using the denaturation information obtained from the Winmelt
profile analysis software, the optimal temperature gradient and running
time for each amplified exon of the GNRHR were determined using a
diagonal TGGE. Once the conditions for each exon were optimized, each
PCR product was denatured and renatured in the absence or presence
of the comparable PCR product from genomic DNA of a healthy vol-
unteer to examine homo- or heterozygotic mutations. Samples with a
final volume of 10 mL were denatured (95 C, 5 min), allowed to reanneal
(55 C, 10 min), and analyzed in parallel on a polyacrylamide gel. Elec-
trophoresis was performed at 280 V. Gels were then silver stained to
allow the identification of DNA. PCR products that revealed an abnor-
mal pattern, i.e. the presence of heteroduplexes in addition to the ho-
moduplexes, were subjected to bidirectional DNA sequence analysis
using either the same primers as those used for PCR amplification or
nested primers.
Functional studies of the GnRH receptor
All cell culture reagents were supplied by Life Technologies, Inc.
(Gaithersburg, MD). GenePorter reagent was obtained from Gene
Therapy System (San Diego, CA), myo-[2-3H]inositol was purchased
from NEN Life Science Products (Boston, MA), GnRH agonist (des-
Gly10[d-Ala6]GnRH ethylamide) was obtained from Sigma (St. Louis,
MO), and AG-X8 resin was purchased from Bio-Rad Laboratories, Inc.
(Hercules, CA).
Site-directed mutagenesis
A hemagglutinin protein (HA)-tagged human GNRHR (hGNRHR)
complementary DNA clone provided by Dr. Thomas Gudermann (29)
was used as a template for generating hGNRHR mutants. To generate the
Thr32Ile hGNRHR mutant, the Thr codon ACC was replaced with the Ile
codon ATC using the QuickChange site-directed mutagenesis kit (Strat-
agene, La Jolla, CA) and a pair of complementary mutagenic primers
(sense, 59-CAACCTCCCCACTCTGATCTTGTCTGGAAAAGATCCG-
39; antisense, 59-CGGATCTTTTCCAGACAAGATCAGAGTGGGGA-
GGTTG-39) according to the manufacturer’s protocol. To generate the
other three mutants, two-stage PCR-based mutagenesis was performed.
To generate the Cys200Tyr mutant, the Cys codon TGC was replaced with
the Tyr codon TAC using the following primers: sense, 59-TAACACAC-
TACAGTTTTTCACAAT-39; and antisense, 59-ATTGTGAAAAACTG-
TAGTGTGTTA-39. To generate Leu266Arg, the Leu codon CTA was
replaced with the Arg codon CGA using the following primers: sense,
59-CTGAAGACTCGAAAAATGACGGTT-39; and antisense, 59-AAC-
CGTCATTTTTCGAGTCTTCAG-39. To generate Cys279Tyr, Cys (TGC)
was replaced with Arg (TAC) with the following primers: sense, 59-
ATTTACTGTCTACTGGACTCCCTA-39; and antisense, 59-TAGGG-
AGTCCAGTAGACAGTAAAT-39. The sequence of the mutated
hGNRHR was confirmed by bidirectional sequence analysis.
Immunofluorescence detection of tagged GnRH receptors
To determine the expression of the natural and mutant GnRH re-
ceptors, COS-7 cells were plated on glass-bottom 35-mm tissue culture
dishes (MatTek Corp., Ashland, MA) and transiently transfected with 2
mg wild-type or mutant hGNRHR constructs using GenePorter. After
48 h, cells were rinsed with PBS, fixed for 30 min at room temperature
with 4% formaldehyde, washed with PBS, and blocked with 1% BSA-
PBS for 30 min at room temperature. After blocking, cells were washed
with PBS, incubated overnight at 37 C with 5 mg/ml anti-HA-fluorescein
antibody (clone 12CA5, Roche Molecular Biochemicals, Indianapolis,
IN), washed four times with phosphate-buffered saline, and examined
using a Bio-Rad Laboratories, Inc. (MRC-1024 multiphoton system),
confocal laser microscope.
Inositol phosphate (IP) assay
The protocol used for measurement of total IP accumulation was an
adaptation of that described by Panchenko et al. (30). COS-7 cells were
transiently transfected by electroporation with 2 mg/well wild-type or
mutant hGNRHR constructs and seeded into six-well tissue culture
plates. After 24 h, cells were incubated in inositol-free DMEM for 2 h,
with subsequent addition of 2 mCi/well myo-[2-3H]inositol, followed by
the addition of 10 mmol/L LiCl 15 min later. Cells were further incu-
bated for 14 h and stimulated with 100 nmol/L GnRH agonist for 45 min.
Cells were extracted on ice twice with 20 mmol/L formic acid. Lysates
were neutralized to pH 7.5 with 7.5 mmol/L HEPES and 150 mmol/L
KOH and centrifuged at 14,000 3 g for 2 min. After the protein content
was measured (Coomassie Plus protein assay reagent, Pierce Chemical
Co., Rockford, IL), supernatants were loaded onto a 0.5-mL AG-X8 resin
anion exchange column previously equilibrated with 2 mL 1 mol/L
NaOH, 2 mL 1 mol/L formic acid, and 5 3 5 mL ddH2O. The columns
were then washed with 5 mL ddH2O followed by 5 mL 5 mmol/L borax
and 60 mmol/L sodium formate, and IP was eluted with 3 mL 0.9 mol/L
ammonium formate and 0.1 mol/L formic acid. A 500-mL aliquot was
counted, the counts were corrected for protein content, and results were
expressed as the fold increase compared with the control plasmid
(pcDNA3).
Results
In vivo studies: subjects and mode of inheritance
A total of 108 probands were examined for mutations in
the GNRHR. Table 1 shows the breakdown of the individuals
into diagnostic subcategories. Forty-eight patients had IHH
with normal olfaction. Sixty patients had IHH and anosmia/
hyposmia (Kallmann syndrome). Although the vast majority
of patients in each subcategory had congenital disease, seven
patients had adult-onset IHH. Fourteen patients across both
subgroups had partial variants of the condition.
The same 108 patients were also classified according to
their presumed mode of inheritance, maintaining the dis-
TABLE 1. Breakdown of HH patients according to diagnosis
n GNRHR mutants
Hypogonadotropic hypogonadism
Congenital HH
Autosomal recessive 5 2
Autosomal dominant 8 0
X-Linked 0 0
Unknown (either autosomal or
X-linked)
1 0
Sporadic 18 2
Adult onset
Sporadic 4 0
Partial variants
Partial HH-sporadic 1 0
Fertile eunuch-sporadic 3 1
No pedigree information 8 0
Total 48 5
Hypogonadotropic hypogonadism 1 anosmia
Kallmann syndrome
Autosomal recessive 4 0
Autosomal dominant 11 0
X-Linked 3 0
Unknown (either autosomal or
X-linked)
1 0
Sporadic 29 0
IHH but in a family with KS-dominant 1 0
IHH but in a family with KS-recessive 2 0
Delayed puberty 1 anosmia-dominant 1 0
Delayed puberty 1 anosmia-sporadic 1 0
Partial variants
Partial KS-dominant 1 0
Partial KS-sporadic 2 0
Fertile eunuch variant-sporadic 3 0
No pedigree information 1 0
Total 60 0
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tinction between normosmic and anosmic individuals. No
pedigree information was available for a total of 9 individuals.
Familial cases. Of the 48 patients with congenital hypogona-
dotropic hypogonadism and normal olfaction, 5 were clas-
sified as autosomal recessive. GNRHR mutations were iden-
tified in 2 of these 5 families (patients 1 and 4; Table 1). Stated
alternatively, 40% of normosmic hypogonadotropic hypo-
gonadism probands whose pedigrees were consistent with
an autosomal recessive mode of inheritance were found to
have a mutated GnRH receptor. In 2 other autosomal reces-
sive families, parents of the affected individuals were mem-
bers of a consanguineous union, but there were no females
among the affected subjects; both probands were negative for
mutations in GNRHR. Six probands with hypogonadotropic
hypogonadism and anosmia (in either the proband or family
member) were also classified with an autosomal recessive
mode of inheritance. However, no GNRHR mutations were
identified in these individuals. No GNRHR mutation was
identified in any other familial case of IHH.
Nonfamilial cases. Of the nonfamilial cases (i.e. sporadic), a
total of 18 individuals with normosmic IHH were studied.
Two patients (no. 2 and 3) were found to have mutations. One
patient (no. 5) with a partial variant of the condition was also
found to have a mutation. Twenty-nine patients with spo-
radic KS were also studied; no mutations were identified. In
total, the percentage of mutations in all patients with non-
anosmic IHH was 5 of 48, or 10.4%. If noncongenital cases are
excluded (i.e. adult onset), the percentage rises to 5 of 41, or
12.2%.
Clinical phenotype. Table 2 summarizes the clinical pheno-
types of the five patients found to have GNRHR mutations.
Three of the five patients were male. Patients 2 and 5 were
evaluated at the Reproductive Endocrine Unit of Massachu-
setts General Hospital, whereas patient 4 was evaluated off-
site. Frequent blood sampling in the General Clinical Re-
search Center in both patients 2 and 5 revealed an apulsatile
LH pattern. However, as summarized in Fig. 1, there were
striking differences between the two men on gonadal exam-
ination. Patient 2 had testicular volumes of 1.4 and 2 cc,
whereas patient 5 had testicular volumes of 15 and 17 cc. The
testicular size of patient 4 at the time of presentation is
unknown.
Differences between the female patients affected with
GNRHR mutations were also apparent (Table 2). Although
patient 1 presented with small breasts, patient 3 was noted
to have Tanner III breasts at initial examination. Patient 1 had
low gonadotropin and E2 levels. However, patient 3 had LH
of 6.9 mIU/mL, FSH of 8.9 mIU/mL, and E2 of 139.5 pmol/L.
In contrast to the male patients, patients 1 and 3 had low
amplitude pulses on baseline frequent sampling.
In vitro studies
Mutational analysis. Six nucleotide sequence abnormalities
were described in five patients. Four changes were novel.
Figure 2 diagrams the corresponding amino acid changes
against the other mutations previously reported in the
literature.
In patient 2 a cytosine in exon 1 was changed to thymidine
at position 95, resulting in a threonine being replaced by
isoleucine at residue 32 (Thr32Ile) near the junction of the
N-terminus and the first transmembrane domain. In the
same patient exon 2 contained a guanine to adenine mutation
at position 599, resulting in a cysteine being replaced by a
tyrosine at amino acid 200 (Cys200Tyr) in the second extra-
cellular loop.
In patient 3 a thymidine in exon 3 was changed to a guanine
at nucleotide 797, causing a leucine to be replaced by an arginine
at residue 266 (Leu266Arg) in the third intracellular loop. In exon
1 a mutation of an adenine to a guanine changed glutamine at
residue 106 into an arginine (Gln106Arg) in the first extracellular
loop. This mutation has been previously described (10).
Patient 4 was one of two patients to have a homozygous
mutation. A guanine was changed to an adenine at position
836, resulting in a cysteine being replaced by a tyrosine
(Cys279Tyr) in the sixth transmembrane domain.
Patient 5 contained the homozygous mutation Gln106Arg.
Patient 1 contained the compound heterozygotic mutations
Gln106Arg and Arg262Gln, both of which have been previ-
ously described (10, 31).
Polymorphisms. Some patients were found to have changes in
the coding sequence of GNRHR of unknown significance.
One individual with congenital IHH was found to be het-
erozygous for a GNRHR mutation (Arg262Gln). TGGE and
sequencing of the remaining exons failed to identify a second
coding sequence abnormality. One individual was found to
have a change in the last base pair of exon 2 (nucleotide 741),
changing a cytosine to a thymidine; however, this coding
change was conservative with the amino acid histidine re-
maining at position 247. Again, no coding sequence abnor-
mality was found in the remaining exons. In 3 additional
cases, individuals were positive on TGGE, but subsequent
sequencing localized the base pair change to the intron be-
tween exons 1 and 2. Because this change occurred in 2 of the
50 healthy volunteers, it would appear that this change has
no influence on the IHH/KS phenotype. One normal vol-
unteer was also found to be heterozygous for the Gln106Arg
mutation.
Functional studies of the mutant receptors. The presence of
hGNRHR proteins at the cell surface of COS-7 cells tran-
siently transfected with plasmids encoding wild-type and
mutant hGNRHR constructs was determined by immuno-
cytochemistry. Confocal fluorescence microscopy revealed a
similar cellular presence of wild-type and mutant receptors
in each case (Table 2).1
The ability of the receptors to transduce a signal after
GnRH agonist stimulation was assessed by measuring IP
accumulation, an indicator of phospholipase C activity. Stim-
ulation of COS-7 cells transiently transfected with wild-type
hGNRHR construct resulted in a 5.2-fold increase in intra-
cellular IP levels, whereas all four of the novel mutant
hGNRHRs failed to respond to GnRH agonist stimulation
(Table 2 and Footnote 1).
1 Be´de´carrats, G. Y., M. Beranova, F. Kada, S. B. Seminara, P. M. Corin,
and U. B. Kaiser, manuscript in preparation.
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Discussion
This screening study of a large and well characterized
population of hypogonadotropic patients for mutations in
the coding sequence of the GnRH receptor demonstrates that
1) patients with GNRHR mutations manifest a broad spec-
trum of phenotypes; 2) GNRHR mutations account for 40%
of autosomal recessive IHH in subjects with a normal sense
of smell; 3) GNRHR mutations also occur in individuals with
sporadic disease, but with a lower frequency; and 4) GNRHR
mutations do not occur in patients with IHH and defects in
olfaction. Four novel mutations in the receptor were also
identified in this study. Despite cellular expression and pres-
ence on the cell surface, Thr32Ile, Cys200Tyr, Leu266Arg, and
Cys279Tyr hGNRHR mutants were unable to respond to
GnRH stimulation in vitro and resulted in loss of receptor
function. Given the breadth of phenotypes described in this
study, this report raises questions about the role of GnRH
induced gonadotropin stimulation.
The GnRH receptor is a member of the rhodopsin-like G
protein-coupled receptor family. Activation of these recep-
tors is associated with conformational changes that facilitate
coupling with G proteins and allow the receptor to transition
between inactive and active states (32). Site-directed mu-
tagenesis and conformational modeling have been used to
study the effects of specific changes within the receptor;
however, correlating mutations within the GNRHR-coding
sequence to changes in structural conformation and to spe-
cific clinical phenotypes has been challenging.
Within the receptor protein, mutations have been de-
scribed in the amino-terminus, first extracellular loop, trans-
membrane domains 3–7, and third intracellular loop (10–15).
This study is the first to describe a mutation, Cys200Tyr, in the
second extracellular loop. All of the mutations described in
this study resulted in a loss of receptor function. Moreover,
an HA tag was used on the mutant constructs to demonstrate
that the decreases in IP accumulation were not due to loss of
hGNRHR cell surface expression.
An important finding of this study is that mutations that
cause the same functional changes in the GNRHR can lead
to strikingly different clinical phenotypes. Nowhere is the
breadth of phenotypes more dramatic than in two of the male
patients described in this study (patients 2 and 5). Both pa-
tients have IHH and an apulsatile LH secretory pattern.
Patient 2 has prepubertal testes, whereas patient 5 has a
testicular size in the normal male range. Individuals such as
patient 5 with hypogonadism but normal sized testes (with
or without spermatogenesis) have been termed fertile eu-
nuchs, a phrase originally coined to reflect a primary pitu-
itary deficiency of LH, but normal FSH secretion (33, 34).
Although patient 2 is a novel compound heterozygote
(Thr32Ile, Cys200Tyr), patient 5 has a homozygous GNRHR
mutation (Gln106Arg) that has been described previously to
reduce GnRH binding and IP signaling (10). Therefore,
Gln106Arg mutants may be capable of transmitting GnRH
signal, albeit in a reduced fashion. How this signal results in
normal testicular growth is not clear.
Pooled FSH samples during patient 5’s frequent sampling
study revealed a level of 2.4 IU/L. Could this FSH be suf-
ficient to account for patient 5’s normal testicular size? Pa-
tient 2 had a similar pooled FSH level of 2.7 IU/L and yet had
prepubertal-sized testes. Caron reported a patient with a
GNRHR mutation and an FSH level of 3.3 IU/L (normal
range, 1.2–11) with bilateral cryptorchidism and a testicular
volume less than 3 (12). As several assays of unknown com-
FIG. 1. Comparison of 2 patients (no. 2 and 5) with respect to testicular volume (TV), neuroendocrine profile, and GNRHR mutations. The graphs
represent serum LH levels drawn every 10 min for 12 h. The shaded area represents the normal range for LH levels as defined in 20 normal
men (16).
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parability are involved, quantitative comparisons cannot be
made. However, the presence of a normal serum level of FSH
a priori cannot, by itself, account for the normal testicular
growth of patient 5. What is even more difficult to reconcile
in patient 5 is his level of testicular growth in the face of
hypogonadal testosterone levels, suggesting that other fac-
tors, perhaps gonadotropin independent, may also play an
important role in gonadal development. Further data from
our group has demonstrated the subsequent development of
gonadotropin pulsatility in patient 5 after hCG stimulation,
suggesting an effect of testosterone, whether direct or
indirect, in modulating pituitary responsiveness to GnRH
(Pitteloud N., P. A. Boepple, S. DeCruz, S. B. Valkenburgh,
W. F. Crowley, and F. J. Hayes, submitted for publication).
Studying patients with shared GNRHR mutations also
provides some important insights. Patient 5 with his ho-
mozygous Gln106Arg mutation demonstrated no LH pulses
on frequent blood sampling, yet he appears to be the least
affected proband phenotypically in this patient cohort. Pa-
tient 3 shares one mutation (Gln106Arg) with patient 5,
whereas her other allele contains the novel missense muta-
tion, Leu266Arg, in the third intracellular loop. She presented
with breast development, measurable gonadotropins and E2,
and three LH pulses in 12 h. Patient 1 also has the Gln106Arg
mutation, whereas her second allele contains the mutation
Arg262Gln, also located in the third intracellular loop.
Although patient 1 presented with lower baseline gonad-
otropins and E2, she did have pulsatile LH activity (five
pulses over 12 h). Although patients 3 and 5 had modest
responses to a single bolus of 100 mg GnRH iv, patient 1
had no gonadotropin response. Therefore, in patients with
GNRHR mutations, a gonadotropin response, albeit small, to
a single pharmacological GnRH stimulation test seems to
bear a loose correlation to phenotype, whereas pulsatile LH
activity (as obtained in these 12-h windows) does not bear a
clear relationship to the clinical presentation.
Although studying patients with identical GNRHR muta-
tions is important, genotype/phenotype correlations are not
easy to make, whether comparing identical genotypes across
sexes or within a family. For example, patient 1 has the
identical genotype (Gln106Arg, Arg262Gln) as the first patient
reported with a GNRHR mutation, a male with partial pu-
berty, 8-cc testes, spermatogenesis, normal gonadotropin in-
crements to 100 mg GnRH administered iv, and low ampli-
tude LH pulsations every 2 h (10). Yet, patient 1 had absence
of breast development, one nonestrogen-induced menstrual
bleed, no gonadotropin responses to 100 mg GnRH, iv, and
erratic low amplitude LH pulsations, suggesting that patient
FIG. 2. Schematic of the GnRH receptor, adapted from Ref. 12. Mutations previously described in the literature are shaded in dark gray. Novel
mutations identified in this study are outlined with a thick black line.
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1 had a more severe phenotype, at least from a neuroendo-
crine perspective (31). Other reports in the literature describe
different gender discrepancies. For example, two sisters with
breast development had gonadotropin levels that responded
to a single injection of GnRH, whereas their brother with
complete IHH had no gonadotropin response (13). Therefore,
there may be sexually dimorphic responses to GNRHR mu-
tations at both pituitary and gonadal levels. Although con-
tinued studies may help to elucidate further correlations, it
is clear that no single clinical trait can be used to include or
exclude the presence of a GNRHR mutation except the pres-
ence of anosmia.
In a previous screening study without subclassification
of phenotype or mode of inheritance (11), GNRHR muta-
tions were identified in just 1 of 46 patients with normos-
mic IHH, yielding a frequency of GNRHR mutations of
2.2%. The current report not only classifies patients on the
basis of smell, but also on the complexity of phenotype (i.e.
partial vs. complete hypogonadotropic hypogonadism)
and the presumed mode of inheritance (i.e. dominant,
recessive, X-linked, sporadic). In this cohort of 108 pa-
tients, 5 individuals had GNRHR mutations. When these
patients were rephenotyped on the basis of smell, all 5
patients with GNRHR mutations were in the normosmic
group (5 of 48, or 10.4%). When those 48 normosmic IHH
probands were recategorized according to the mode of
inheritance, 5 appeared to be from autosomal recessive
kindreds, whereas 18 had no familial involvement. Two of
the 5 probands with GNRHR mutations (patients 1 and 4)
were from an autosomal recessive subgroup (n 5 5), yield-
ing a frequency of 2 of 5, or 40%. Therefore, although the
number of cases with recessive inheritance was small (n 5
5), the proportion of cases with GNRHR mutations within
that subgroup was high (40%). Viewed from another per-
spective, it is likely that another gene(s) accounts for au-
tosomal recessive IHH. The remaining 3 probands with
GNRHR mutations (2, 3, and 5) were sporadic, yielding a
frequency of 3 of 18, or 16.7%, in normosmic congenital
IHH.
That the subtype of IHH (congenital vs. adult onset, IHH
vs. KS) and mode of inheritance may serve as important
guideposts for genetic testing has important implications for
clinical practice. For example, the presence of a GNRHR
mutation is not necessarily a contraindication to the use of
exogenous, pulsatile GnRH, albeit at higher doses (31). Such
therapy reduces the risk of multiple gestation in individuals
seeking ovulation induction (35). In addition, patients with
GNRHR mutations are unlikely to pass IHH onto their chil-
dren, an increasingly important consideration for couples
pursuing fertility therapy.
In summary, this study examines the frequency and dis-
tribution of GNRHR mutations in a large, heterogeneous
population of patients with IHH. Patients bearing mutations
demonstrate a broad range of IHH, from complete to partial
defects. Receptor mutations may account for a larger pro-
portion of cases of IHH than previously appreciated. Patients
with autosomal recessive or sporadic normosmic IHH
should be considered candidates for screening.
References
1. Franco B, Guioli S, Pragliola A, et al. 1991 A gene deleted in Kallmann’s
syndrome shares homology with neural cell adhesion and axonal path-finding
molecules. Nature. 353:529–536.
2. Legouis R, Hardelin JP, Levilliers J, et al. 1991 The candidate gene for the
X-linked Kallmann syndrome encodes a protein related to adhesion molecules.
Cell. 67:423–435.
3. Legouis R, Lievre CA, Leibovici M, Lapointe F, Petit C. 1993 Expression of
the KAL gene in multiple neuronal sites during chicken development. Proc
Natl Acad Sci USA. 90:2461–2465.
4. Habiby RL, Boepple P, Nachtigall L, Sluss PM, Crowley Jr WF, Jameson JL.
1996 Adrenal hypoplasia congenita with hypogonadotropic hypogonadism.
Evidence that DAX-1 mutations lead to combined hypothalamic and pituitary
defects in gonadotropin production. J Clin Invest. 98:1055–1062.
5. Seminara SB, Achermann JC, Genel M, Jameson JL, Crowley Jr WF. 1999
X-Linked adrenal hypoplasia congenita: a mutation in DAX1 expands the
phenotypic spectrum in males and females. J Clin Endocrinol Metab.
84:4501–4509.
6. Tabarin A, Achermann JC, Recan D, et al. 2000 A novel mutation in DAX1
causes delayed-onset adrenal insufficiency and incomplete hypogonadotropic
hypogonadism. J Clin Invest. 105:321–328.
7. Kakar SS, Musgrove LC, Devor DC, Sellers JC, Neill JD. 1992 Cloning,
sequencing, and expression of human gonadotropin releasing hormone
(GnRH) receptor. Biochem Biophys Res Commun. 189:289–295.
8. Chi L, Zhou W, Prikhozhan A, et al. 1993 Cloning and characterization of the
human GnRH receptor. Mol Cell Endocrinol. 91:R1–R6.
9. Whitcomb RW, Crowley Jr WF. 1990 Clinical review 4: diagnosis and treat-
ment of isolated gonadotropin-releasing hormone deficiency in men. J Clin
Endocrinol Metab. 70:3–7.
10. de Roux N, Young J, Misrahi M, et al. 1997 A family with hypogonadotropic
hypogonadism and mutations in the gonadotropin-releasing hormone recep-
tor. N Engl J Med. 337:1597–1602.
11. Layman LC, Cohen DP, Jin M, et al. 1998 Mutations in gonadotropin-releasing
hormone receptor gene cause hypogonadotropic hypogonadism. Nat Genet.
18:14–15.
12. Caron P, Chauvin S, Christin-Maitre S, et al. 1999 Resistance of hypogonadic
patients with mutated GnRH receptor genes to pulsatile GnRH administration.
J Clin Endocrinol Metab. 84:990–996.
13. de Roux N, Young J, Brailly-Tabard S, Misrahi M, Milgrom E, Schaison G.
1999 The same molecular defects of the gonadotropin-releasing hormone re-
ceptor determine a variable degree of hypogonadism in affected kindred. J Clin
Endocrinol Metab. 84:567–572.
14. Kottler ML, Chauvin S, Lahlou N, et al. 2000 A new compound heterozygous
mutation of the gonadotropin-releasing hormone receptor (L314X, Q106R) in
a woman with complete hypogonadotropic hypogonadism: chronic estrogen
administration amplifies the gonadotropin defect. J Clin Endocrinol Metab.
85:3002–3008.
15. Pralong FP, Gomez F, Castillo E, et al. 1999 Complete hypogonadotropic
hypogonadism associated with a novel inactivating mutation of the gonado-
tropin-releasing hormone receptor. J Clin Endocrinol Metab. 84:3811–3816.
16. Spratt DI, O’Dea LStL, Schoenfeld D, Butler J, Rao PN, Crowley Jr WF. 1988
Neuroendocrine-gonadal axis in men: frequent sampling of LH, FSH, and
testosterone. Am J Physiol. 254:E658–E666.
17. Santoro N, Butler J, Filicori M, Crowley Jr WF. 1988 Alterations of the
hypothalamic GnRH interpulse interval sequence over the normal menstrual
cycle. Am J Physiol. 255:E696–E701.
18. Nachtigall LB, Boepple PA, Pralong FP, Crowley Jr WF. 1997 Adult-onset
idiopathic hypogonadotropic hypogonadism-a treatable form of male infer-
tility. N Engl J Med. 336:410–415.
19. Waldstreicher J, Seminara SB, Jameson JL, et al. 1996 The genetic and clinical
heterogeneity of gonadotropin-releasing hormone deficiency in the human.
J Clin Endocrinol Metab. 81:4388–4395.
20. Filicori M, Santoro N, Merriam GR, Crowley Jr WF. 1986 Characterization of
the physiologic pattern of episodic gonadotropin secretion throughout the
human menstrual cycle. J Clin Endocrinol Metab. 62:1136–1144.
21. Santen RJ, Bardin CW. 1973 Episodic luteinizing hormone secretion in man.
Pulse analysis, clinical interpretation, physiologic mechanisms. J Clin Invest.
52:2617–2628.
22. Welt CK, Adams JM, Sluss PM, Hall JE. 1999 Inhibin A and inhibin B response
to gonadotropin withdrawal depends on stage of follicle development. J Clin
Endocrinol Metab. 84:2163–2169.
23. Crowley Jr WF, Beitins IZ, Vale W, et al. 1980 The biologic activity of a potent
analogue of gonadotropin-releasing hormone in normal and hypogonado-
tropic men. N Engl J Med. 302:1052–1057.
24. Filicori M, Butler JP, Crowley Jr WF. 1984 Neuroendocrine regulation of the
corpus luteum in the human. Evidence for pulsatile progesterone secretion.
J Clin Invest. 73:1638–1647.
PREVALENCE AND SPECTRUM OF GNRHR MUTATIONS 1587
 by on May 18, 2010 jcem.endojournals.orgDownloaded from 
25. Whitcomb RW, O’Dea LStL, Finkelstein JS, Heavern DM, Crowley Jr WF.
1990 Utility of free alpha-subunit as an alternative neuroendocrine marker of
gonadotropin-releasing hormone (GnRH) stimulation of the gonadotroph in
the human: evidence from normal and GnRH-deficient men. J Clin Endocrinol
Metab. 70:1654–1661.
26. Whitcomb RW, Sangha JS, Schneyer AL, Crowley Jr WF. 1989 Improved
measurement of free alpha subunit of glycoprotein hormones by assay with
use of a monoclonal antibody. Clin Chem. 34:2022–2025.
27. Abrams ES, Murdaugh SE, Lerman LS. 1990 Comprehensive detection of
single base changes in human genomic DNA using denaturing gradient gel
electrophoresis and a GC clamp. Genomics. 7:463–475.
28. Wartell RM, Hosseini SH, Moran Jr CP. 1990 Detecting base pair substitutions
in DNA fragments by temperature-gradient gel electrophoresis. Nucleic Acids
Res. 18:2699–2705.
29. Grosse R, Shoneberg T, Shultz G, Gudermann T. 1997 Inhibition of gona-
dotropin-releasing hormone receptor signaling by expression of a splice vari-
ant of the human receptor. Mol Endocrinol. 11:1305–1317.
30. Panchenko MP, Saxena K, Li Y, et al. 1998 Sites important for PLCb2 acti-
vation by the G protein bg subunit map to the sides of the b propeller structure.
J Biol Chem. 23:28298–28304.
31. Seminara SB, Beranova M, Oliveira LMB, Martin KA, Crowley Jr WF, Hall
JE. 2000 Successful use of pulsatile gonadotropin-releasing hormone (GnRH)
for ovulation induction and pregnancy in a patient with GnRH receptor mu-
tations. J Clin Endocrinol Metab. 85:556–562.
32. Farfel Z, Bourne HR, Iiri T. 2000 The expanding spectrum of G protein
diseases. N Engl J Med. 340:1012–1020.
33. Pasqualini RQ, Bur EG. 1950 Sindrome hipoandrogenico con gametogenesis
conservada: clasificacion de la insuficiencis testicular. Rev Assoc Med Argent.
64:6.
34. McCullagh EP, Beck JC, Schaffenburg CA. 1953 A syndrome of eunuchoid-
ism with spermatogenesis, normal urinary FSH and low or normal ICSH:
“fertile eunuchs.” J Clin Endocrinol Metab. 13:489–509.
35. Martin KA, Hall JE, Adams JM, Crowley Jr WF. 1993 Comparison of exog-
enous gonadotropins and pulsatile gonadotropin-releasing hormone for in-
duction of ovulation in hypogonadotropic amenorrhea. J Clin Endocrinol
Metab. 77:125–129.
Joint Meeting—11th Annual Meeting of the European Neuropeptides Club (ENC)
& American Summer Neuropeptides Conference
May 7–12, 2001
Jerusalem (Kibbutz Ma’ale HaChamisha) and Tel Aviv, Israel
For further information: Illana Gozes, Ph.D., Professor of Clinical Biochemistry, Sackler Faculty of Medicine,
Tel Aviv University, Tel Aviv 69978, Israel. Phone: 972-3-640-7240; Fax: 972-3-640-8541; E-mail: igozes@post.
tau.ac.il or meeting@unitours.co.il.
1588 BERANOVA ET AL. JCE & M † 2001
Vol. 86 † No. 4
 by on May 18, 2010 jcem.endojournals.orgDownloaded from 
